---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018161"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T13:20:58.861206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY

## Summary
- R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.
- Initiated multi-dose cohort in Phase 1 trial of Decoy20 after positive preliminary results from second cohort.
- Granted key patent in January 2024 to expand intellectual property portfolio.
- Accepted for poster presentation at ASCO Annual Meeting on June 1, 2024, highlighting initial Phase 1 Decoy20 data.

## SEC filing metadata
- accession: 0001493152-24-018161
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/0001493152-24-018161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018161
- JSON: https://secwatch.observer/filing/0001493152-24-018161.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018161.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/0001493152-24-018161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.